The cost effectiveness of dry powder antibiotics for the treatment of pseudomonas aeruginosa in patients with cystic fibrosis

PharmacoEconomics

Volumn 32, Issue 2, 2014, Pages 159-172

  Tappenden, Paul ^a   Harnan, Sue ^a   Uttley, Lesley ^a   Mildred, Matthew ^a   Walshaw, Martin ^b   Taylor, Christopher ^c   Brownlee, Keith ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^c SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTI-BACTERIAL AGENTS; COLISTIN; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DECISION SUPPORT TECHNIQUES; DRY POWDER INHALERS; HUMANS; MODELS, ECONOMIC; PNEUMONIA, BACTERIAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TOBRAMYCIN; YOUNG ADULT;

EID: 84894053561     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0122-x     Document Type: Article

References (24)

1. Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2010. 2011; p. 1-67.
2. Davies JC, Alton EW, Bush A. Clinical review: Cystic fibrosis. BMJ. 2007;335(7632):1255-9.
3. Quittner AL, Sweeney S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol. 2000;25(6):403-14.
4. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):54-61.
5. Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: Arandomised study. Thorax 2012;68(4):344-50.
6. Tappenden P, Harnan S, Uttley L, et al. Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Assessment report to the National Institute for Health and Clinical Excellence. 2012. Available from http://www.nice.org.uk/. Accessed: 21 Feb 2013.
7. European Medicines Agency. Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. EMA Research Guideline 2009. Available from http://www.ema.europa.eu/docs/. Accessed 01 Dec 2012.
8. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. NICE, London 2008.
9. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J. 2007;29:522-6.
10. Forest Laboratories UK Ltd. A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium and nebulised TNSFI (tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with Pseudomonas aeruginosa lung infection - Clinical Study Report. 2009; p. 1-8411.
11. Yi MS, Britto MT, Wilmott RW, et al. Health values of adolescents with cystic fibrosis. J Paediatr. 2003;142:133-40.
12. Bradley J, Blume S, Stafford M, et al. Quality of life and health utility in patients with cystic fibrosis. European Respiratory Society Conference; 2010.
13. Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcome. 2005;3:56.
14. Anyanwu AC, McGuire A, Rogers CA, et al. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax. 2001;56(3):218-22.
15. Association of the Royal Pharmaceutical Society of Great Britain. British National Formulary Number 62. 2011.
16. Forest Laboratories UK Ltd. Colobreathe patient access scheme submission to the National Institute for Health and Clinical Excellence. 2012.
17. Patient Access Schemes Liaison Unit, National Institute for Health and Clinical Excellence. Process for advising on the feasibility of implementing a patient access scheme - interim. 2009. Available from: http://www.nice.org.uk/ media/FCC/CC/PASLUProcessGuide.pdf. Accessed 30 Jan 2013.
18. Department of Health. NHS reference costs 2010-2011. 2012. London, Department of Health.
19. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006.
20. Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibros. 2003;2:120-8.
21. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: Aprospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J. 1997;10:896-900.
22. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: Comparing hospital and home care. J Cyst Fibros. 2005;4:239-47.
23. Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making. University of Sheffield, Decision Support Unit. p. 1-24; 2011.
24. Novartis Pharmaceuticals. Colistimethate sodium powder (Colobreathe®) and tobramycin powder for inhalation (TOBI Podhaler®) for the treatment of pseudomonas lung infection in cystic fibrosis - Novartis submission to NICE. 2011.